This is Part 5 of 5 in the “The Weight of Empire: Novo Nordisk’s Fight for Survival” series.
The factory in Kalundborg had been running three shifts a day for two years, producing semaglutide at a pace that would have seemed impossible a decade ago. Now the third shift was gone. Half the second shift was gone. The parking lot, which had once overflowed onto the access road, was two-thirds empty. The drug was still selling. The company was still standing. But something essential had been removed, and everyone who walked through those gates could feel its absence.
Kalundborg sits on the western coast of Zealand, an hour and a half from Copenhagen by car. It is a small city – forty thousand people, a medieval church, a fjord that freezes in hard winters – and for the past decade, it had been transformed by Novo Nordisk’s manufacturing expansion. The company had built what was arguably the largest semaglutide production facility in the world here, a complex of stainless-steel buildings and clean rooms and refrigerated warehouses that employed thousands of people and generated an economic gravity that pulled the entire region into its orbit.
New housing developments had gone up to accommodate the workers. Restaurants opened. A private school expanded. The local football club got a new sponsor. Kalundborg, which had spent decades watching its younger residents leave for Copenhagen, was growing for the first time in a generation, and the reason was a single molecule produced inside those gleaming buildings.
Now the layoffs had arrived, and the gravity reversed.
Henrik Madsen – the production supervisor who had been quoted in DR, Denmark’s public broadcaster, describing the restructuring as “like being told your family is being reorganized” – was still employed. His position had survived the cuts. But four members of his twelve-person team had not, and the work that twelve people had done was now distributed among eight, with no reduction in quality standards and no tolerance for production delays.
He drove to work each morning on roads that were quieter than they had been six months ago. The coffee shop near the plant entrance, which had done brisk business in the early mornings, had reduced its hours. The temp agency that had supplied supplemental workers during peak production periods had closed its Kalundborg office entirely.
Henrik did not think of himself as a political person. He voted in elections because his parents had taught him it was a duty, not because he believed it made a difference. But he had started reading the business pages of Berlingske with an attention he had never given them before, tracking the stock price, the analyst notes, the quarterly guidance, as though these numbers might tell him something about his own future that his managers could not or would not.
What the numbers told him was that things were not getting better. They were getting different – which was, in his experience, what people said when things were getting worse but they didn’t want to use the word.
In Indianapolis, the mood was exactly the opposite.
Eli Lilly’s headquarters hummed with the energy of a company that had found itself in the right place at the right time with the right molecule. Zepbound was selling faster than their manufacturing could produce it, which was, in the pharmaceutical industry, the most luxurious problem a company could have. Their stock price had reached a record high. Their pipeline was delivering. And the competitive landscape, which had looked like a two-horse race twelve months earlier, was starting to look like something less balanced.
Lilly’s advantage was not just Zepbound’s superior efficacy numbers, though those numbers mattered enormously. It was structural. Lilly did not have a foundation controlling 77% of its votes. Lilly did not have a dual chairman whose philanthropic obligations competed with corporate strategy. Lilly did not have to negotiate drug prices with a board chairman who was simultaneously responsible for funding Danish cancer research. Lilly had a conventional corporate governance structure – a board, a CEO, shareholders with voting rights proportional to their economic interest – and in a crisis, that conventionality had become an advantage.
Lilly could move fast. Lilly could acquire Metsera without checking with a Foundation trustee. Lilly could set prices without balancing charitable commitments. Lilly could restructure without triggering a national identity crisis in a small European country. These were not advantages of innovation or talent. They were advantages of structure – the kind of advantages that only become visible when the wind changes direction.
The irony was bitter enough to taste. Novo Nordisk’s governance model had been held up for years as a case study in long-term thinking – proof that a company could be profitable and purposeful, competitive and charitable, Danish and global. Business school professors had written papers about it. ESG analysts had praised it. Conference speakers had cited it as evidence that stakeholder capitalism could work.
None of those people were writing papers now.
The compounding pharmacy lawsuits ground forward through the American court system with the particular slowness of litigation that neither side could afford to lose. Novo Nordisk’s legal team had filed more than 130 cases, a wall of litigation designed to exhaust the smaller compounders through sheer legal expense. Some of the smaller operations had already settled or shut down, unable to sustain the cost of defending themselves against a company with functionally unlimited legal resources.
But the larger compounders were fighting. They had organized, pooled legal funds, and hired Washington lobbyists who argued – with some success – that Novo Nordisk was using the legal system to maintain a monopoly on a drug that millions of Americans could not afford.
In a congressional hearing in January, a compounding pharmacy operator from Florida testified before a Senate subcommittee. She was fifty-two years old, a licensed pharmacist, and spoke with the calm certainty of someone who believed she was on the right side of history.
“I have patients who lost eighty, ninety, a hundred pounds on compounded semaglutide,” she said. “Patients who could not afford the branded drug at $1,349 a month. Patients whose insurance wouldn’t cover it. Patients who had tried every diet, every exercise program, every other medication, and failed. And now Novo Nordisk wants me to stop helping them. Not because what I’m doing is dangerous – my products are tested, my facility is inspected, my pharmacists are licensed. They want me to stop because what I’m doing is affordable.”
The senator chairing the hearing – a Republican from a state with a significant pharmaceutical industry presence – nodded sympathetically while committing to nothing. The hearing produced no legislation. But the testimony migrated to social media, where it accumulated millions of views and reinforced a narrative that Novo Nordisk’s communications team had been fighting since the lawsuits began: that the company cared more about protecting its pricing power than about the patients it claimed to serve.
Doustdar, watching clips of the hearing on his phone during a flight to Tokyo, understood that the litigation war was unwinnable in the court of public opinion, regardless of what happened in the courts of law. He could not say this publicly. Saying it publicly would undermine the legal strategy. But he could feel the ground shifting – the slow, corrosive erosion of a company’s reputation that happens when the story about you becomes simpler and more damaging than the reality.
In Copenhagen, the Foundation’s trustees convened their quarterly meeting in a conference room overlooking the harbor. The agenda was, for the first time anyone could remember, dominated by a single question: the charitable budget.
The Foundation had committed 11.2 billion Danish kroner in grants for 2025 – a record amount, spread across research institutions, hospitals, and cultural organizations throughout Denmark and beyond. Those commitments were legally binding. They could not be casually reduced or deferred. But the Foundation’s income – primarily dividends from Novo Nordisk – was falling, and the endowment’s total value had declined with the stock price.
A trustee with a background in academic research laid out the options. The Foundation could honor its existing commitments by drawing down reserves, which would weaken its financial position and potentially threaten its AAA credit rating. Or it could begin scaling back future grant-making, which would mean cutting funding to the research institutions and hospitals that had come to depend on Foundation money.
“There is a third option,” Sorensen said from his seat at the head of the table. “The company recovers. Dividends stabilize. And we fulfill our obligations without drawing down reserves.”
The room was quiet. Everyone understood that this third option depended on Doustdar’s U-shaped recovery materializing – and that the evidence for that recovery remained, at best, aspirational.
“What is the timeline for recovery, Lars?” asked a trustee who ran one of Denmark’s largest hospitals, an institution that received significant Foundation funding.
“Mike believes we’ll see inflection in the second half of 2026. Volume growth in emerging markets, oral formulation uptake in the U.S., and cost savings from the restructuring should begin to compound.”
“And if it doesn’t compound by the second half?”
Sorensen’s expression did not change. “Then we will have a different conversation.”
It was, beneath the diplomatic language, an admission that the Foundation’s charitable mission was now hostage to a corporate turnaround that nobody in the room – including, perhaps, Sorensen himself – was certain would succeed. The institution that existed to fund Danish science and medicine was dependent on a stock price set by American pharmaceutical politics, Eli Lilly’s marketing budget, and the spending habits of compounding pharmacy customers in Florida and Texas.
The meeting lasted three hours. No decisions were made about the 2026 budget. The deferral was itself a decision – a bet that the numbers would improve before the commitment letters had to be signed.
Through February, small signals began to emerge from unexpected corners of the globe.
In Brazil, Novo Nordisk’s Wegovy launch had exceeded projections by thirty percent, driven by aggressive pricing and a partnership with the country’s largest pharmacy chain. In India, where the company had introduced a generic-priced version of semaglutide for the diabetes market, prescriptions were growing at a rate that surprised even the most optimistic analysts on Doustdar’s team. In the Middle East, where Doustdar had spent much of his career building Novo’s commercial presence, the GLP-1 market was expanding rapidly, fueled by some of the highest obesity rates in the world.
These were not transformative numbers. Brazil was not going to replace the United States in Novo Nordisk’s revenue mix. India’s pricing was so low that volume growth barely moved the margin needle. The Middle East was growing but remained a small fraction of global sales.
What the numbers represented was something more subtle: proof of concept for the strategy Doustdar had been articulating since his first day. Lower prices, higher volume, broader access. A pharmaceutical company that made less money per patient but served more patients. A commercial model built on the recognition that the era of premium GLP-1 pricing was over and that the companies that adapted to the new reality would survive, while those that mourned the old reality would not.
It was, in a sense, exactly what the Foundation’s charter demanded – a company that served the greatest number of patients, not just the wealthiest ones. And it was exactly what the Foundation’s financial position made difficult – a strategy that depressed margins in the short term to build volume in the long term, requiring patience from an institution whose charitable commitments could not wait.
On a clear morning in late February, Doustdar arrived at the Bagsvaerd campus before dawn. He had been doing this more frequently – arriving early, walking the corridors before they filled with people, sitting in the cafeteria with a cup of coffee and a tablet displaying the overnight sales data from markets that operated while Denmark slept.
He looked out the window of his office. The construction cranes were gone. Two of the building projects had been completed; the rest had been paused. The skyline was different from the one Jorgensen had surveyed twenty months ago – less cluttered, less ambitious, less certain of what it was reaching toward.
His phone rang. Sorensen.
“I’ve been thinking about the Foundation’s position,” Sorensen said, without preamble. “We cannot reduce charitable commitments this year. The reputational damage would be worse than the financial cost. We will draw on reserves if necessary.”
“That’s your decision, Lars.”
“It is. But I want you to understand what it means. It means the Foundation is betting on your recovery timeline. If 2026 does not show improvement, the 2027 conversation will be very different.”
“I understand.”
“Good.” A pause. “Mike, I believe in what you’re building. I want you to know that.”
It was the most personal thing Sorensen had said to him since his appointment. Doustdar was not sure whether it was encouragement or a warning. Perhaps it was both.
He hung up and turned back to the window. The parking lot was filling with cars – fewer than a year ago, but the people who arrived were moving quickly, their steps purposeful in the cold morning air. The company was still here. Wounded, diminished, contested, and uncertain, but still here. The drug was still being manufactured in Kalundborg, still being prescribed by doctors from Copenhagen to Sao Paulo to Mumbai. The molecule still worked. The patients still needed it.
What had changed was everything around the molecule – the price, the governance, the workforce, the competitive landscape, the relationship between the company and the nation that had built it. Novo Nordisk would survive. Doustdar was as certain of this as he was of anything. But the company that survived would not be the one that had entered the crisis. It would be smaller. Leaner. Less Danish in its sensibility and more global in its ambitions. Less protected by the Foundation’s shield and more exposed to the forces that shield had been designed to deflect.
The weight of empire, he was learning, was not the burden of power. Power could be restructured, renegotiated, redistributed. The true weight was the burden of consequence – the accumulated cost of every decision made and not made, every job cut and not cut, every price set and not set, every promise kept and broken. It was the weight of nine thousand people whose livelihoods had been traded for a cost structure. The weight of patients who needed a drug they could not afford. The weight of a Foundation whose charitable mission depended on a stock price that the Foundation’s own governance was helping to depress. The weight of a nation that had placed its industrial pride in a single company and watched that company decide it could no longer afford to carry it.
There was no resolution to this weight. There was only the carrying of it – day after day, quarter after quarter, decision after decision – until the shape of what remained became clear enough to call a future.
The sun rose over Bagsvaerd. The office filled with light. And Novo Nordisk, the company that had changed the world’s relationship with obesity, began another day of trying to change its relationship with itself.
This is a work of fiction. While inspired by real events and public information, all characters, dialogue, and internal deliberations are entirely imagined. Any resemblance to actual private conversations or decisions is coincidental.
